GSK plc
Long book
$599.2M
Q1 2026
Positions
13
Top-10 weight
97%
concentration
Last quarter
+5.9%
SPY +14.8%
Turnover
13%
of book per quarter
Strategy in plain words
auto-generated from filingsGSK plc is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $599.2M US long book across 13 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: CRISPR THERAPEUTICS AG, WAVE LIFE SCIENCES LTD, BIONTECH SE-ADR, VIR BIOTECHNOLOGY INC, IDEAYA BIOSCIENCES INC.
We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2025
-25.0%
Q1 2026
+5.9%
Sector allocation
Healthcare 100%
Long book by quarter
What does GSK plc own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| CRSP CRISPR THERAPEUTICS AG | Healthcare | 3.2M | $153.2M | 25.6% | Held |
| WVE WAVE LIFE SCIENCES LTD | Healthcare | 18.2M | $132.3M | 22.1% | Held |
| VIR VIR BIOTECHNOLOGY INC | Healthcare | 8.6M | $76.6M | 12.8% | Held |
| IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.3M | $44.4M | 7.4% | Held |
| LYEL LYELL IMMUNOPHARMA INC | Healthcare | 1.5M | $30.3M | 5.1% | Held |
| CYTK CYTOKINETICS INC | Healthcare | 340.4K | $22.4M | 3.7% | Held |
| SPRO SPERO THERAPEUTICS INC | Healthcare | 9.2M | $21.5M | 3.6% | Held |
| FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.8M | $13.7M | 2.3% | Held |
| CVRX CVRX INC | Healthcare | 1.0M | $9.5M | 1.6% | Held |
| NKTX NKARTA INC | Healthcare | 3.2M | $6.6M | 1.1% | Held |
| RGNX REGENXBIO INC | Healthcare | 271.5K | $2.3M | 0.4% | Held |